SOURCE: Novo Nordisk A/S

July 03, 2008 07:49 ET

Treasury Stock

BAGSVAERD, DENMARK--(Marketwire - July 3, 2008) - Status re Novo Nordisk's holding of its own shares (30 June 2008)

In continuation of the company's announcement dated 31 January 2008 concerning a planned share repurchase programme, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 30 June 2008 owned 16,571,430 of its own B shares of DKK 1, corresponding to a total nominal value of DKK 16,571,430 or 2.61% of the total share capital.

In the second quarter of 2008 a total of 2,810,000 B shares were repurchased, and 296,660 B shares were disposed of to employees in connection with employee incentive programs. Furthermore, 12,960,000 B shares were cancelled on 13 June 2008. Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com

Stock Exchange Announcement no 42 / 2008

Copyright © Hugin AS 2008. All rights reserved.

Contact Information

  • For further information please contact:

    Media:

    Outside North America:
    Elin K Hansen
    Tel: (+45) 4442 3450
    Email Contact

    Investors:

    Outside North America:
    Mads Veggerby Lausten
    Tel: (+45) 4443 7919
    Email Contact

    Hans Rommer
    Tel: (+45) 4442 4765
    Email Contact

    In North America:
    Sean Clements
    Tel: (+1) 609 514 8316
    Email Contact

    In North America:
    Christian Qvist Frandsen
    Tel: (+1) 609 919 7937
    Email Contact